Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
Tislelizumab is now approved for seven indications in China
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Tislelizumab is now approved in nine indications in China
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Subscribe To Our Newsletter & Stay Updated
